

No.: 17/2026 /CV-MP

*Ha Noi, May 29, 2026*

## **INFORMATION DISCLOSURE**

**To: - State Securities Commission**

**- Hanoi Stock Exchange**

**1. Name of Organization: MEDIPLANTEX NATIONAL PHARMACEUTICAL  
JOINT STOCK COMPANY**

**- Securities code: MED**

**- Address: 358 Giai Phong, Phuong Liet, Ha Noi**

**- Person responsible for information disclosure: Mr. Mai Nhat Thanh**

Type of disclosed information:      Periodic      ☒ Extraordinary      Upon request

**2. Contents of disclosure:**

**- Resolution of the Board of Directors regarding Approval of contracts and transactions between Mediplantex National Pharmaceutical Joint Stock Company and its related party**

**3. This information was published on the company's website on 29/05/2026, as in the link:  
<http://www.mediplantex.com/cổ-đông/công-bố-thông-tin.html>**

**We hereby certify that the information provided is true and correct and we bear the full responsibility to the law.**

**MEDIPLANTEX NATIONAL  
PHARMACEUTICAL JSC  
GENERAL DIRECTOR**



**Mai Nhat Thanh**

No.: 05/2026/NQ-HĐQT

Hanoi, May 29, 2026

**RESOLUTION**  
**THE BOARD OF DIRECTORS**  
**OF MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY**

- Pursuant to the Law on Enterprises of the Socialist Republic of Viet Nam and its guiding documents;
- Pursuant to the Law on Securities of the Socialist Republic of Viet Nam and its guiding documents;
- Pursuant to the Charter of Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company (as amended and supplemented for the 12th time under the Resolution of the General Meeting of Shareholders dated June 26, 2024);

**RESOLUTION:**

**Article 1: Approval of the following matters:**

Approval of contracts and transactions between Mediplantex National Pharmaceutical Joint Stock Company and its related party as follows:

- Contracting party: AN HY Pharmaceutical One Member Company Limited – a related party of an internal person: Mr. Nguyen Ngoc Xuan Trang, Chairman of the Board of Directors;
- Transaction details:  
**Type of contract:** Pharmaceutical trading (sale and purchase) contract  
**Estimated transaction value:** VND 20,000,000,000  
**Implementation period:** Fiscal year 2026
- The General Director is assigned to carry out all relevant procedures and execute the above-mentioned contracts and transactions with the related party, ensuring operational efficiency and that the total value of such related contracts and transactions in 2026 does not exceed 35% of the Company's total assets as recorded in the most recent financial statements, in compliance with applicable laws, the Company's Charter, and internal regulations.

**Article 2: Effectiveness and Implementation:**

This Resolution shall take effect from the date of signing. The Board of Directors, the Board of Management, and all relevant individuals and departments shall be responsible for its implementation.

Recipients:

- As listed above;
- Filed at: Secretariat.

**ON BEHALF OF THE BOARD OF DIRECTORS**  
**CHAIRMAN OF THE BOARD OF DIRECTORS**



Nguyen Ngoc Xuan Trang